A promising innovation in the fight against the influenza virus has been unveiled by a team of Irish medical researchers, headed by Anna Boykenhorst from the Harvard T.H. Chan School of Public Health. These scientists have engineered a nasal spray formulated with the monoclonal antibody CR9114, which specifically targets hemagglutinin—a crucial protein component of the virus. Findings from preclinical studies and Phase I clinical trials, detailed in the journal Science Translational Medicine, attest to the new agent’s considerable efficacy.
The pressing need for novel approaches to flu prevention and treatment persists, given that the virus causes hundreds of thousands of fatalities globally each year due to its rapid mutation rate. Past endeavors utilizing monoclonal antibodies frequently fell short because systemic administration resulted in insufficient concentrations within the nasopharynx. Adopting a spray formulation successfully circumvented this hurdle by delivering the therapeutic agent directly to the site where the infection initially replicates.
During trials involving animals, such as mice and cynomolgus monkeys, the treatment demonstrated excellent tolerability and no significant adverse reactions. The monkeys received the spray twice prior to being challenged with the H1N1 strain. Treated subjects exhibited substantially lower viral loads in their nasal passages compared to the control group. Furthermore, the virus became undetectable in samples within a week, whereas in animals given the placebo, the infection lingered much longer.
The initial clinical investigation, involving 143 volunteers, validated the drug’s safety profile in humans. The medicine achieved a high concentration in the nasal mucosa—up to 3850 nanograms per milliliter—a figure vastly surpassing levels obtained via systemic delivery of similar agents. Tests revealed that even six hours post-application, nasal swab samples retained the capacity to effectively bind to various strains of Influenza A and B viruses.
The development must now advance through subsequent phases of clinical testing, which are necessary to confirm its effectiveness under real-world conditions. Nevertheless, the data obtained thus far foster optimism regarding the emergence of a robust prophylactic tool capable of substantially mitigating disease severity and curbing the virus’s spread throughout the population.
About the Author
